This site is intended for U.S. healthcare professionals.
Visit Pfizer MedicalSign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentContact
HomeAbout NGENLAEfficacy & SafetyPhase 3 Main Study + SafetyPhase 3 OLE Study + SafetyPhase 2 Study + SafetyDosingDosingDosingAdministrationMyNgenla PlanIGF-1 MonitoringAccess & SupportAccess &
SupportUS Formulary CoverageAccessPatient SupportDevice Training EducationRequest a Pfizer RepDownloadable MaterialsVideos Access & SupportNGENLA has the broadest preferred commercial coverage in the US of any pediatric long-acting growth hormone (LAGH).1 Pfizer is here to assist you in supporting your patients as they get started on treatment.
US Formulary CoverageAccessPatient SupportDevice Training EducationRequest a Pfizer RepThe Pfizer Bridge Program® can support your patients through their NGENLA journey in many ways
InsuranceAssist with understanding the insurance process
CopayCopay assistance for eligible patients*
ShippingArrange for the first shipment from the pharmacy and address issues that may lead to pharmacy delays or treatment interruptions
Device trainingDevice training education by an experienced nurseSubmit a complete Patient Enrollment Form to the Pfizer Bridge Program to get started
Enrollment in the Pfizer Bridge Program is not required to access NGENLASign up patients via enrollment form Submit an enrollment form via fax at 1‑800-479-2562 or efax at WWW.PATIENTSUPPORTNOW.ORG and enter patient support code 8004792562
Download a Patient
Enrollment Form LoadingSign up patients via HCP portal Complete the Patient Enrollment Form digitally via the Pfizer Bridge Program HCP Portal
Pfizer Bridge Program HCP Portal
LoadingIf the patient and/or caregiver is unavailable to sign the enrollment form, you can still submit and direct them to the below website to complete their consents: https://pfizerbridgeprogram.com/BridgeProvider/s/esign-ondemand. The Pfizer Bridge Program will also make an outreach to the patient to obtain any missing required consents.
Pfizer FAS will communicate with you when action is needed for your patients enrolled in the Pfizer Bridge Program.FAS, field access specialist.TERMS AND CONDITIONS
By using this copay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:Patients are not eligible to use this card if they are enrolled in a state or federally-funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, or a state prescription drug assistance program. Patient must have private insurance. Offer is not valid for cash-paying patients. Patients are responsible for as little as a $0 monthly copayment based upon program utilization. The value of this copay card is limited to a maximum of $6,000 per calendar year. This copay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value of this copay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the copay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the copay card, as may be required. You should not use the copay card if your insurer or health plan prohibits use of manufacturer copay cards. This copay card is not valid where prohibited by law. Copay card cannot be combined with any other savings, free trial or similar offer for the specified prescription. Copay card will be accepted only at participating pharmacies. If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer. This copay card is not health insurance. Offer good only in the U.S. (including Puerto Rico, the U.S. Virgin Islands, and Guam). Copay card is limited to 1 per person during this offering period and is not transferable. A copay card may not be redeemed more than once per 30 days per patient. No other purchase is necessary. No membership fee. Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires [12/31/2025]. For more information, visit our website www.NGENLA.com, call 1-800-645-1280 or visit pfizer.com. NGENLA Copay Program, PO Box 220746, Charlotte, NC 28222-0746 or visit pfizerbridgecopay.com.Reference:Data on file. Pfizer Inc., New York, NY.Access and SupportDownloadable MaterialsConvenient resources to support your patients as they begin treatment with NGENLA.
Learn More LoadingTo report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0454
You are now leaving PfizerPro You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-SMT-USA-0454
INDICATIONNGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONS
Somatrogon is contraindicated in patients with acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with growth hormones.NGENLA is contraindicated in patients with hypersensitivity to somatrogon or any of its excipients. Somatrogon is contraindicated in patients with closed epiphyses. Somatrogon is contraindicated in patients with active malignancy due to the risk of malignancy progression. Somatrogon is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy. Somatrogon is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to the risk of sudden death. WARNINGS AND PRECAUTIONS
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure has been reported with somatropin. The safety of continuing NGENLA treatment for the approved indication who concurrently develop these illnesses has not been established.Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with somatropin. Inform patients and caregivers that such reactions are possible and that prompt medical attention should be sought if allergic reaction occurs.There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment should be completed, prior to instituting therapy with NGENLA. Discontinue NGENLA if there is evidence of recurrent malignancy. In childhood cancer survivors who were treated with radiation to the brain/head for their first neoplasm and who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Intracranial tumors, in particular meningiomas, were the most common of these second neoplasms. Monitor all patients with a history of GHD secondary to an intracranial neoplasm while on NGENLA therapy for progression or recurrence of the tumor. Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, thoroughly consider the risks and benefits of starting NGENLA in these patients. If treatment with NGENLA is initiated, carefully monitor these patients for development of neoplasms. Monitor patients on NGENLA therapy carefully for increased growth or potential malignant changes of preexisting nevi. Advise patients and/or caregivers to report marked changes in behavior, onset of headaches, vision disturbances, and/or changes in skin pigmentation or changes in the appearance of preexisting nevi. Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses. New-onset type 2 diabetes mellitus has been reported in patients receiving growth hormone. Patients with undiagnosed pre-diabetes and diabetes mellitus may experience worsened glycemic control and become symptomatic. Monitor glucose levels periodically in all patients receiving NGENLA, especially in those with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or pre-diabetes should be monitored closely. The doses of antidiabetic agents may require adjustment when NGENLA is initiated. Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in patients treated with somatropin. Symptoms usually occurred within the first 8 weeks after the initiation of somatropin therapy. In all reported cases, IH-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of somatropin dose. NGENLA should be temporarily discontinued in patients with clinical or fundoscopic evidence of IH. If IH is confirmed, restart treatment with NGENLA at a lower dose after IH-associated signs and symptoms have resolved. Fluid retention during NGENLA therapy may occur. Clinical manifestations of fluid retention (eg, edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent. Patients receiving growth hormone therapy who have or are at risk for pituitary hormone deficiencies may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of NGENLA treatment. Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism. Undiagnosed/untreated hypothyroidism may prevent an optimal response to NGENLA therapy. In patients with GH deficiency, central (secondary) hypothyroidism may first become evident or worsen during treatment with growth hormone therapy. Therefore, patients should have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or appropriately adjusted when indicated. Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Evaluate pediatric patients with the onset of a limp or complaints of persistent hip or knee pain. NGENLA increases growth rate, and progression of preexisting scoliosis can occur in patients who experience rapid growth. Growth hormone treatment has not been shown to increase the occurrence of scoliosis. Monitor patients with a history of scoliosis for disease progression. Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared with adults. Consider pancreatitis in patients who develop persistent severe abdominal pain. When growth hormone is administered subcutaneously at the same site over a long period of time, lipoatrophy may result. Rotate injection sites when administering NGENLA to reduce this risk. There have been reports of sudden death after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. NGENLA is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome. Serum levels of phosphorus, alkaline phosphatase, and parathyroid hormone may increase with NGENLA therapy. If a patient is found to have abnormal laboratory tests, monitor as appropriate. ADVERSE EFFECTS
Adverse reactions reported in ≥5% of patients treated with NGENLA are injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, and oropharyngeal pain. Health care providers should supervise the first injection and provide appropriate training and instruction for the proper use of all NGENLA devices. INDICATION
NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.